A Phase 3 interventional study of Glepaglutide in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 1 site in Denmark. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-22.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Short Bowel Syndrome with a site in Denmark — 4 open to participants now, 5 under way, 3 of them phase 3. Short Bowel Syndrome · Denmark.
Among the 22 studies in Short Bowel Syndrome with a site in Denmark, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 18th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →4 of the 22 studies in Short Bowel Syndrome with a site in Denmark are open now. Recruiting first, the newest first:
VectivBio AG · Sites in Denmark, United States, Argentina and 19 more countries
Ages 18+
Zealand Pharma · Sites in Denmark, United States, Austria and 11 more countries
Ages 18–90
Hanmi Pharmaceutical Company Limited · Sites in Denmark, United States, Belgium and 5 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 13
First in 2004; this study’s year is marked. 5 started in 2021.
This study's enrollment of 12 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 65 across the 21 interventional studies, 20 across the 1 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Short Bowel Syndrome with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Short Bowel Syndrome with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS). The trial will also investigate whether glepaglutide is safe during long-term use. All participants in the trial will receive glepaglutide injections.
Participants will have 14 visits with the study doctor. At 2 of these, participants will spend 48 hours at the trial site, one visit at the start of the trial and one after 24 weeks of treatment with glepaglutide. At all visits, participants will meet with trial staff and will have blood tests along with other clinical checks and tests done. Participants will be asked about their health and medical history.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
Drug: Glepaglutide
Glepaglutide will be delivered in a single-use autoinjector.
Also known as: ZP1848
Change in Absorption of Wet Weight/Fluids
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Energy
Oral intake minus fecal excretion: measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed. Energy absorption was measured by bomb calorimetry.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Carbohydrates
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Lipids
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Proteins
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Sodium
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Potassium
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Calcium
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Absorption of Magnesium
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly Parenteral Support (PS) Volume
Only for participants with Short Bowel Syndrome with Intestinal Failure (SBS-IF). PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Volume
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Carbohydrates
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Carbohydrates
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Lipids
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Lipids
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Proteins
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Proteins
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Sodium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Sodium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Potassium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Potassium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Change in Weekly PS Magnesium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 12
Change in Weekly PS Magnesium
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
Time frame: from Week 0 (baseline) to Week 24
Anti-glepaglutide Antibodies
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56
Time frame: Week 56
Reactivity to ZP1848
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. Anti-drug antibodies (ADA) positive samples were analyzed for reactivity to ZP1848.
Time frame: Week 56
Cross-reactivity to Glucagon-like Peptide-2 (GLP-2)
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. ADA positive samples were analyzed for cross-reactivity to glucagon-like peptide-2 (GLP-2).
Time frame: Week 56
Glepaglutide Neutralizing Antibodies
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56
Time frame: Week 56
The trial was conducted at a single site in Denmark. The study was planned to enroll a minimum of 6 and a maximum of 16 patients with SBS intestinal failure (SBS-IF) or SBS intestinal insufficiency (SBS-II). First patient recruited was on 10 Aug 2021.
| Milestone | Once-weekly Glepaglutide |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| g/day | Baseline Group - Week 0 | Week 24 Group |
|---|---|---|
| Change in Absorption of Wet Weight/Fluids | 841.6 ± 1839.10 | 1240.0 ± 1529.74 |
Oral intake minus fecal excretion: measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed. Energy absorption was measured by bomb calorimetry.
| kJ/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Energy | 1037.7 ± 1182.18 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| g/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Carbohydrates | 39.8 ± 48.31 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| g/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Lipids | 10.5 ± 26.56 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| g/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Proteins | 1.0 ± 1.65 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| mmol/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Sodium | 28.0 ± 83.64 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| mmol/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Potassium | 1.9 ± 26.44 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| mmol/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Calcium | 1.3 ± 6.42 |
Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.
| mmol/day | Once-weekly Glepaglutide |
|---|---|
| Change in Absorption of Magnesium | -2.2 ± 5.06 |
Only for participants with Short Bowel Syndrome with Intestinal Failure (SBS-IF). PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mL | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly Parenteral Support (PS) Volume | -4688.1 ± 3150.67 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mL | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Volume | -5312.6 ± 5463.54 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Carbohydrates | -3547.1 ± 6375.32 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Carbohydrates | -4914.8 ± 2452.10 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Lipids | -260.3 ± 1361.60 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Lipids | -42.2 ± 1869.08 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Proteins | -879.3 ± 1939.60 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| kJ | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Proteins | -1057.7 ± 983.93 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Sodium | -473.7 ± 440.09 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Sodium | -475.7 ± 506.37 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Potassium | -35.6 ± 73.88 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Potassium | -58.9 ± 51.64 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Magnesium | 1.6 ± 9.02 |
Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.
| mmol | Once-weekly Glepaglutide |
|---|---|
| Change in Weekly PS Magnesium | -5.8 ± 14.84 |
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56
| Participants | Once-weekly Glepaglutide |
|---|---|
| Anti-glepaglutide Antibodies | 9 |
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. Anti-drug antibodies (ADA) positive samples were analyzed for reactivity to ZP1848.
| Participants | Once-weekly Glepaglutide |
|---|---|
| Reactivity to ZP1848 | 8 |
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. ADA positive samples were analyzed for cross-reactivity to glucagon-like peptide-2 (GLP-2).
| Participants | Once-weekly Glepaglutide |
|---|---|
| Cross-reactivity to Glucagon-like Peptide-2 (GLP-2) | 1 |
Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56
| Participants | Once-weekly Glepaglutide |
|---|---|
| Glepaglutide Neutralizing Antibodies | 8 |
Collected over Safety data cover the period since the first administrated dose till Week 56.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Once-weekly Glepaglutide | 1/10 (10%) | 6/10 (60%) | 10/10 (100%) |
| Event | Once-weekly Glepaglutide |
|---|---|
| Device related sepsisInfections and infestations | 2/10 |
| Urinary tract infectionInfections and infestations | 2/10 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Stoma obstructionInjury, poisoning and procedural complications | 1/10 |
| Altered state of consciousnessNervous system disorders | 1/10 |
| Crohn's diseaseGastrointestinal disorders | 1/10 |
| NauseaGastrointestinal disorders | 1/10 |
| Pelvic fluid collectionGastrointestinal disorders | 1/10 |
| Pulmonary massRespiratory, thoracic and mediastinal disorders | 1/10 |
| Stoma site abscessInfections and infestations | 1/10 |
| Event | Once-weekly Glepaglutide |
|---|---|
| Gastrointestinal stoma complicationInjury, poisoning and procedural complications | 8/10 |
| Injection site painGeneral disorders | 7/10 |
| Injection site reactionGeneral disorders | 5/10 |
| Oedema peripheralGeneral disorders | 5/10 |
| Weight decreasedInvestigations | 3/10 |
| DizzinessNervous system disorders | 3/10 |
| Injection site pruritusGeneral disorders | 3/10 |
| Abdominal painGastrointestinal disorders | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/10 |
| DehydrationMetabolism and nutrition disorders | 3/10 |
| Age, Categorical(Participants) | Once-weekly Glepaglutide |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 3 |
| Age, Continuous(years) | Once-weekly Glepaglutide |
|---|---|
| Mean | 54.6 ± 15.85 |
| Sex: Female, Male(Participants) | Once-weekly Glepaglutide |
|---|---|
| Female | 5 |
| Male | 5 |
| Race (NIH/OMB)(Participants) | Once-weekly Glepaglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Once-weekly Glepaglutide |
|---|---|
| Denmark | 10 |
| BMI(kg/m^2) | Once-weekly Glepaglutide |
|---|---|
| Mean | 24.1 ± 2.32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Feb 2023, 17 months.
Results were first posted in Nov 2024, 1 year 9 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 17 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glepaglutide